News | November 01, 2022
Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Subscribe To Our Newsletter & Stay Updated
